- 115.6k views
Beyond Breathless: Innovative Approaches to PAH Management
Pulmonary arterial hypertension (PAH) is a progressive and debilitating disease that affects the arteries in the lungs, leading to increased pulmonary arterial pressure and right heart failure. Despite significant advances in the management of PAH in recent years, it remains a challenging disease to treat, and many patients continue to experience significant symptoms and reduced quality of life. However, there are several innovative approaches to PAH management that are currently being explored and show promise in improving outcomes for patients. One such approach is the use of combination therapy. While single-agent therapy has traditionally been the first-line treatment for PAH, recent studies have shown that combining different classes of drugs can lead to better outcomes. For example, combining an endothelin receptor antagonist with a phosphodiesterase type 5 inhibitor has been shown to improve exercise capacity and reduce clinical worsening in patients with PAH. Another promising approach is the use of novel drugs that target specific pathways involved in the development of PAH. For example, selexipag, a prostacyclin receptor agonist, has been shown to improve exercise capacity and reduce hospitalization rates in patients with PAH. Similarly, macitentan, a dual endothelin receptor antagonist, has been shown to improve exercise capacity and reduce clinical worsening in patients with PAH.
About the Speaker
Dr. Bhagwan Mantri
Consultant Pulmonologist and Critical care specialist
Upcoming Case Discussions
Gynaecologist’s Guide to Ovarian Cancer
Join us for a special webinar on World Ovarian Cancer Day, titled "Gynaecologist’s Guide to Ovarian Cancer." This expert-led session will delve into the latest advancements in early diagnosis, risk stratification, and evidence-based management of ovarian cancer. Tailored for gynecologists and healthcare professionals, the session will also explore real-world case discussions and multidisciplinary treatment approaches. Let’s come together to raise awareness and empower clinicians in the fight against this silent but deadly disease
Massive Transfusion Protocol
Massive Transfusion Protocol (MTP) is a standardized medical procedure activated in cases of severe hemorrhage, typically involving the rapid administration of large volumes of blood products. The goal is to restore circulating volume, maintain hemostasis, and prevent the lethal triad of hypothermia, acidosis, and coagulopathy. MTP usually involves a balanced ratio of packed red blood cells, plasma, and platelets, often in a 1:1:1 ratio. Early activation and coordination among trauma teams, laboratory services, and blood banks are essential for its success.
Sleep Apnea and Daytime Fatigue
Sleep Disorder Breathing is a term for a group of conditions with abnormal breathing patterns during sleep. This affects everyday functioning and well being.There are few types of SDB which include upper airways resistance, hypopnea, apnea, catathrenia and heavy snoring. People suffering with SDB can have daytime symptoms that result in poor sleep also. There can also be sleepiness, depressed mood, irritability and cognitive dysfunction.
Author Post
Impact
+
Talks
+
webinar
+
no.of registrations
One liner about speaker
Why is speaker relevant?
Dr. Bhagwan Mantri's Talks on Assimilate
- 18th-May-2023, TIME : 6:00PM - 7:00PM
- 0
Pulmonary arterial hypertension (PAH) is a progressive and debilitating disease that affects the arteries in the lungs, leading to increased pulmonary arterial pressure and right heart failure. Despite significant advances in the management of PAH in recent years, it remains a challenging disease to treat, and many patients continue to experience significant symptoms and reduced quality of life. However, there are several innovative approaches to PAH management that are currently being explored and show promise in improving outcomes for patients. One such approach is the use of combination therapy. While single-agent therapy has traditionally been the first-line treatment for PAH, recent studies have shown that combining different classes of drugs can lead to better outcomes. For example, combining an endothelin receptor antagonist with a phosphodiesterase type 5 inhibitor has been shown to improve exercise capacity and reduce clinical worsening in patients with PAH. Another promising approach is the use of novel drugs that target specific pathways involved in the development of PAH. For example, selexipag, a prostacyclin receptor agonist, has been shown to improve exercise capacity and reduce hospitalization rates in patients with PAH. Similarly, macitentan, a dual endothelin receptor antagonist, has been shown to improve exercise capacity and reduce clinical worsening in patients with PAH.
- 18th-May-2023, TIME : 6:00PM - 7:00PM
- 0
Pulmonary arterial hypertension (PAH) is a progressive and debilitating disease that affects the arteries in the lungs, leading to increased pulmonary arterial pressure and right heart failure. Despite significant advances in the management of PAH in recent years, it remains a challenging disease to treat, and many patients continue to experience significant symptoms and reduced quality of life. However, there are several innovative approaches to PAH management that are currently being explored and show promise in improving outcomes for patients. One such approach is the use of combination therapy. While single-agent therapy has traditionally been the first-line treatment for PAH, recent studies have shown that combining different classes of drugs can lead to better outcomes. For example, combining an endothelin receptor antagonist with a phosphodiesterase type 5 inhibitor has been shown to improve exercise capacity and reduce clinical worsening in patients with PAH. Another promising approach is the use of novel drugs that target specific pathways involved in the development of PAH. For example, selexipag, a prostacyclin receptor agonist, has been shown to improve exercise capacity and reduce hospitalization rates in patients with PAH. Similarly, macitentan, a dual endothelin receptor antagonist, has been shown to improve exercise capacity and reduce clinical worsening in patients with PAH.